Talk:Z3220040
Questions from Lab 10 article
What is the background to the existing problem / disease condition???
Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells
Mozobil- able to mobilise stem cells from bone marrow to blood and doesnt increase mobility of tumor cells in melonoma patients
Treatment for tumor patients- chemotherapy with autologous stem cell transplantation
Before chemotherapy- patients stem cells collected and then transplanted back into patient after chemotherapy, 2 million stem cell required adn can occur through multiple collection sessions, which increases the risk of comtaminating the sample with tumour cells and some patients could not collect enough sample stem cells
Mozobil and Neupogen (filgrastim) solves the above problem Neupogen increases stem cell production in bone marrow Mozobil increases the mobility of stem cells from marrow to blood
Faculty of Medicine at the University of Utah conducted the use of above drugs- they utilized patients with proven poor stem cell mobilizers and potentially poor stem cell mobilizers Found that the majority of patients could produce 2 million stem cells and had successful transplantations
Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization
This study found that for improved response and survival rates from chemotherapy, stems cell must be mobilized and collected for transplantation back into the patient. However there is a risk of potential contamination of the sample by tumour cells. Those with poor stem cell mobilizers were given pleixafor as it was identified as improving stem cell collection.
